Cartesian Therapeutics, Inc. (RNAC) Stock Price & Growth Analysis

Quote Panel

Updated October 22, 2025

1W -4.56 % 1M -8.36 % 3M -32.86 % 1Y -59.47 %

Key Metrics

Market Cap
233.76M
Shares Outstanding
26.00M
Share in Float
9.39M
Dividende
0

Earning Date
06 Nov 2025
Price Target
8.99
Average Volume
67678
Beta
0.3819099

Range
8.46-26.5
Industry
Biotechnology
Website
https://selectabio.com
Sector
Healthcare

Quote Panel

Updated October 22, 2025

1W % 1M % 3M % 1Y %

Key Metrics

Market Cap
Shares Outstanding
Share in Float
Dividende

Earning Date
No Data
Price Target
Average Volume
Beta

Range
Industry
Website
Sector

Fundamentals

N/A

P/E Ratio

235.18x

P/S Ratio

N/Ax

P/B Ratio

N/A

Debt/Equity

-3534.1%

Net Margin

$-0.7

EPS

How RNAC compares to sector?

P/E Ratio

Fundamentals

Relative Strength

RNAC

Sector

Top 5 RS in Group

Symbol	Company	RS	5-Day Perf.

Forecast

$370K

-81%

2026-Revenue

$3.56

-77%

2026-EPS

$200K

81%

2026-EBITDA

Analyst rating

Strong Sell

Sell

Buy

Neutral

Strong Buy

Buy

Price Target

0.00(N/A)

Number of analyst

Last analyst upgrade/downgrade

BTIG

initialise

Previous: Not converted

2024-12-19

Now: Buy

Cowen & Co.

initialise

Previous: Not converted

2024-08-06

Now: Buy

Oppenheimer

downgrade

Previous: Outperform

2024-07-02

Now: Perform

Oppenheimer

initialise

Previous: Not converted

2024-06-04

Now: Outperform

Forecast

Analyst rating

Last analyst upgrade/downgrade

Earnings Growth

YoY

Current

Estimates

Q3.23

N/A

-2.40
vs 0.05

Q4.23

N/A

-2.40
vs NA

Q1.24

N/A

-1.97
vs -0.17

Q2.24

+871%

0.54
vs -0.07

Q3.24

N/A

-0.69
vs -2.40

Q4.24

N/A

-0.59
vs -2.40

Q1.25

N/A

-0.68
vs -1.97

Q2.25

-7%

0.5
vs 0.54

Q3.25

N/A

-0.85
vs -0.69

Q4.25

N/A

-1.03
vs -0.59

Sales Growth

YoY

Current

Estimates

Q3.23

-68%

6.6M vs 20.7M

Q4.23

-51%

8.3M vs 16.8M

Q1.24

-2%

5.8M vs 5.9M

Q2.24

+537%

33.4M vs 5.2M

Q3.24

-94%

387K vs 6.6M

Q4.24

-109%

-759000.00 vs 8.3M

Q1.25

-81%

1.1M vs 5.8M

Q2.25

-99%

298K vs 33.4M

Q3.25

-31%

266.3K vs 387K

Q4.25

+159%

449.7K vs -759000

Return on Equity

QoQ

Q1.23

-29%

-0.29
vs 0.06

Q2.23

-17%

-0.17
vs -0.29

Q3.23

-15%

-0.15
vs -0.17

Q4.23

+124%

1.24
vs -0.15

Q1.24

+49%

0.49
vs 1.24

Q2.24

-14%

-0.14
vs 0.49

Q3.24

-3216%

-32.16
vs -0.14

Q4.24

+151%

1.51
vs -32.16

Q1.25

+81%

0.81
vs 1.51

Q2.25

-629%

-6.29
vs 0.81

Institutionnal Ownership

QoQ

Q1.23

1
vs NA

Q2.23

1
vs 1

Q3.23

1
vs 1

Q4.23

NA
vs NA

Q1.24

4
vs NA

Q2.24

59
vs 4

1375%

Q3.24

62
vs 59

Q4.24

65
vs 62

Q1.25

68
vs 65

Q2.25

62
vs 68

-9%

Earnings Growth

YoY

Current

Estimates

Q3.23

N/A

-2.40
vs 0.05

Q4.23

N/A

-2.40
vs NA

Q1.24

N/A

-1.97
vs -0.17

Q2.24

+871%

0.54
vs -0.07

Q3.24

N/A

-0.69
vs -2.40

Q4.24

N/A

-0.59
vs -2.40

Q1.25

N/A

-0.68
vs -1.97

Q2.25

-7%

0.5
vs 0.54

Q3.25

N/A

-0.85
vs -0.69

Q4.25

N/A

-1.03
vs -0.59

Sales Growth

YoY

Current

Estimates

Q3.23

-68%

6.6M vs 20.7M

Q4.23

-51%

8.3M vs 16.8M

Q1.24

-2%

5.8M vs 5.9M

Q2.24

+537%

33.4M vs 5.2M

Q3.24

-94%

387K vs 6.6M

Q4.24

-109%

-759000.00 vs 8.3M

Q1.25

-81%

1.1M vs 5.8M

Q2.25

-99%

298K vs 33.4M

Q3.25

-31%

266.3K vs 387K

Q4.25

+159%

449.7K vs -759000

Return on Equity

QoQ

Q1.23

-29%

-0.29
vs 0.06

Q2.23

-17%

-0.17
vs -0.29

Q3.23

-15%

-0.15
vs -0.17

Q4.23

+124%

1.24
vs -0.15

Q1.24

+49%

0.49
vs 1.24

Q2.24

-14%

-0.14
vs 0.49

Q3.24

-3216%

-32.16
vs -0.14

Q4.24

+151%

1.51
vs -32.16

Q1.25

+81%

0.81
vs 1.51

Q2.25

-629%

-6.29
vs 0.81

Institutionnal Ownership

QoQ

Q1.23

1
vs NA

Q2.23

1
vs 1

Q3.23

1
vs 1

Q4.23

NA
vs NA

Q1.24

4
vs NA

Q2.24

59
vs 4

1375%

Q3.24

62
vs 59

Q4.24

65
vs 62

Q1.25

68
vs 65

Q2.25

62
vs 68

-9%

Earnings Growth

Forecast

$370K

-81%

2026-Revenue

$3.56

-77%

2026-EPS

$200K

81%

2026-EBITDA

Analyst rating

Strong Sell

Sell

Buy

Neutral

Strong Buy

Buy

Price Target

0.00(N/A)

Number of analyst

Last analyst upgrade/downgrade

BTIG

initialise

Previous: Not converted

2024-12-19

Now: Buy

Cowen & Co.

initialise

Previous: Not converted

2024-08-06

Now: Buy

Oppenheimer

downgrade

Previous: Outperform

2024-07-02

Now: Perform

Oppenheimer

initialise

Previous: Not converted

2024-06-04

Now: Outperform

N/A

235.18x

N/Ax

N/A

-3534.1%

$-0.7

$370K

$3.56

$200K

Earnings Growth

Latest News

Latest News

Latest News

Earnings Growth

$370K

$3.56

$200K

N/A

235.18x

N/Ax

N/A

-3534.1%

$-0.7